Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1.664 JPY | +1,87% | +1,93% | +1,15% |
25/04 | AstraZeneca opgetogen over omzetgroei door medicijnen tegen kanker | AN |
08/04 | AstraZeneca prijst neurologische gegevens voor Ultomiris, Soliris | AN |
Omzet 2024 * | 201 mld. 1,27 mld. 1,18 mld. | Omzet 2025 * | 198 mld. 1,25 mld. 1,17 mld. | Marktkapitalisatie | 365 mld. 2,3 mld. 2,16 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 52,51 mld. 332 mln. 310 mln. | Nettowinst (verlies) 2025 * | 52,26 mld. 330 mln. 309 mln. | EV/omzet 2024 * | 1,82 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,84 x |
K/w-verhouding 2024 * |
7,62
x | K/w-verhouding 2025 * |
7,36
x | Werknemers | 864 |
Dividendrendement 2024 * |
5,31% | Dividendrendement 2025 * |
5,45% | Vrij verhandelbaar | 46,97% |
1 dag | +1,87% | ||
1 week | +1,93% | ||
Lopende maand | -0,63% | ||
1 maand | -2,09% | ||
3 maanden | -5,26% | ||
6 maanden | +34,81% | ||
Lopend jaar | +1,15% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Akihiko Ishihara
CEO | Chief Executive Officer | 61 | 01-04-86 |
Chairman | 71 | 01-04-77 | |
Sou Busujima
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 71 | 01-04-77 | |
Akihiko Ishihara
CEO | Chief Executive Officer | 61 | 01-04-86 |
Ichiro Tomiyama
COO | Chief Operating Officer | 66 | 01-11-86 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.78% | 9 M€ | +17,30% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 1.664 | +1,87% | 1 546 700 |
25-04-24 | 1.633 | -1,98% | 772 100 |
24-04-24 | 1.666 | +0,97% | 1 043 900 |
23-04-24 | 1.650 | +0,49% | 831 300 |
22-04-24 | 1.642 | +0,61% | 1 447 400 |
uitgestelde koers Japan Exchange, 26 april 2024 om 08:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,15% | 2,3 mld. | |
+11,20% | 8,4 mld. | |
-25,64% | 700 mln. | |
+29,76% | 366 mln. | |
+3,88% | 333 mln. | |
+5,69% | 333 mln. | |
-6,11% | 263 mln. | |
+15,54% | 185 mln. | |
+26,63% | 101 mln. | |
-28,33% | 63,05 mln. |